Yesterday was more of the same and that is actually good for one of the first times this year. The sector continues higher and modestly outperformer the broader markets. The one negative was that ISI noted that there has been a lack of real money interest. In other words, long term institutional money has not […]
May 18 Biotech Update
The sector remains in a precarious position, which is nothing new. ISI had a call yesterday with its technician and the overwhelming view on most of the stocks was that they are at a decision point- the short term chart does not look great but they are at long term support. He tended to lean […]
May 16 Biotech Update
We got some decent news flow to start the week both positive and negative. Who knows how that will balance out in terms of the sector general performance but this should be a week driven by news related moves with ASCO abstracts and the ABBV IPR decision still on deck. 1. The biggest data news […]
May 2 Biotech Update
It was not a great end of the week for the sector. Trading has not been good and earnings were fine but not exciting. As much as the sector has bounced from its recent lows, it still does not feel like sentiment has changed dramatically. It as an odd dynamic that I will talk about […]
April 28 Biotech Update
We have a little bit of news this morning. There is no way I can cover it all especially having a bunch of conference calls to listen to as well. I will focus on the big picture and dig down into a couple of the events. 1. We have been waiting for M&A and it […]
April 27 Biotech Update
This week seems to have started like last week. I think it was actually last Tuesday that the sector suddenly took a dive on no real news and yesterday was certainly not a good day. It remains to be seen if this weakness will continue as we are entering into earnings that could help the […]
Dave-Trading – April Edition
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No positionPreview 2-3 […]
April 11 Biotech Update
I do not think the week is starting with the news everybody wants, i.e. buyouts, but I do think we are getting closer to that point. The sector has been searching for direction at the end of last week but it had a nice run after the AGN/PFE break, so a pause is not unexpected. […]
March 17 Biotech Update
You are missing a lot of private interaction we are mostly using the private feed @CRGTrades to do so, the best way to be updated is to follow us through this link, please fill in all the info needed for easy confirmation! https://www.chimeraresearchgroup.com/twitter-page/ Well, I do not think we really learned anything new yesterday in […]
March 11 Biotech Update
The blast from the past continues as the market and sector continue to weaken. As cheap as large cap biotechs look it is hard to see a stock like CELG break below what was a trading range and not think it will re-test the previous lows in the lower $90s. While the market today started […]
March 9 Biotech Update
Yesterday was certainly a blast from the past with small caps getting crushed and large caps outperforming but only because they are down less than SMID. After the recent run it is not surprising that the run pauses and reverses at resistance. As one could imagine the bears will highlight this as the start of […]
February 18 Biotech Update
We continue to have a short covering rally as the most shorted stocks continue to outperform. This seems to be the mantra of people who want to discount the move but as I said before there is no reason to suspect that the bounce off the lows would be anything but a short covering rally. […]
February 12 Biotech Update
The market remains crazy and the sector is filled with odd moves. Yesterday seemed to be a good day of outperformance for the large caps and today they are red while the market is green. There were some good movers in SMID yesterday and today but not a real rhyme or reason for who outperforms […]
January 28 Biotech Update
The market and sector did not like the FOMC decision or perhaps the wording of the decision. The sector remains in a precarious position. It has already fallen a lot but it remains at critical long term trend lines and if they break we could only be halfway through the decline. There was some talk […]
January 25 Biotech Update
It is a mixed start to the week but at least we have some biotech news to talk about even if it is not exactly what was expected. That being said I still think we are in a macro driven market and it will be hard for any sector to avoid the headwinds (or tailwinds) […]
January 6 Biotech Update
The year is really off to a bad start and I am not sure what will reverse it. You have continued bad news with China, which is continuing the rout in commodities and strengthening the dollar killing emerging markets and it seems like the US market. Outside of some bright spots in the service sector, […]
January 5 Biotech Update
While the market recovered a little into the end of the day yesterday and had a slight positive bias this morning, it is still not looking too healthy. I am not sure if this is simply people selling or buyers being afraid to step in. In terms of the sector, I still think JPM will […]
December 30 Biotech Update
Nothing newsworthy for the sector has happened in the past day. We had a nice rally the other day and perhaps that continues with a positive bias into the end of the year as investors and traders finish up the year but with volumes drying up it is really a toss-up how it will trade. […]
December 29 Biotech Update
I am back and ready to get into the sector again. Some news since I have been gone but for this week I mainly want to focus on 2016 previews and will try to broadly cover both stocks and broader themes. 1. The first topic today is CMRX. That might have been the biggest phase […]
December 14 Biotech Update
We are once again in a macro world and the sector will be driven by it. Of course, even if we were not in a macro world the sector would likely still be underperforming as ASH did not inspire a lot of confidence and the sector offers a lot of chances for tax loss selling […]
